Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies - PubMed (original) (raw)
Review
doi: 10.1159/000446543. Epub 2016 May 11.
Affiliations
- PMID: 27165273
- DOI: 10.1159/000446543
Review
Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies
Daniel P Cardinali et al. Neuroendocrinology. 2017.
Abstract
The metabolic syndrome (MS) is a collection of risk factors for cardiovascular disease, including obesity, hypertension, hyperinsulinemia, glucose intolerance and dyslipidemia. MS is associated with low-grade inflammation of the white adipose tissue, which can subsequently lead to insulin resistance, impaired glucose tolerance and diabetes. Adipocytes secrete proinflammatory cytokines as well as leptin and trigger a vicious circle which leads to additional weight gain largely as fat. The imbalance between inflammatory and anti-inflammatory signals is crucial to aging. Healthy aging can benefit from melatonin, a compound known to possess direct and indirect antioxidant properties, to have a significant protective effect on mitochondrial function, to enhance circadian rhythm amplitudes, to modulate the immune system and to exhibit neuroprotective actions. Melatonin levels decrease in the course of senescence and are more strongly reduced in diseases related to insulin resistance. This short review article analyzes the multiple protective actions of melatonin that are relevant to the attenuation of inflammatory responses and progression of inflammaging and how melatonin is effective to curtail MS in animal models of hyperadiposity. The clinical data supporting the possible therapeutic use of melatonin in human MS are also reviewed. Since attention has been focused on the development of potent melatonin analogs with prolonged effects (ramelteon, agomelatine, tasimelteon, piromelatine) and in clinical trials these analogs were administered in doses considerably higher than those usually employed for melatonin, clinical trials on melatonin in the range of 50-100 mg/day are needed to further assess its therapeutic value in MS.
© 2016 S. Karger AG, Basel.
Similar articles
- Disrupted chronobiology of sleep and cytoprotection in obesity: possible therapeutic value of melatonin.
Cardinali DP, Pagano ES, Scacchi Bernasconi PA, Reynoso R, Scacchi P. Cardinali DP, et al. Neuro Endocrinol Lett. 2011;32(5):588-606. Neuro Endocrinol Lett. 2011. PMID: 22167135 Review. - Melatonin and brain inflammaging.
Hardeland R, Cardinali DP, Brown GM, Pandi-Perumal SR. Hardeland R, et al. Prog Neurobiol. 2015 Apr;127-128:46-63. doi: 10.1016/j.pneurobio.2015.02.001. Epub 2015 Feb 16. Prog Neurobiol. 2015. PMID: 25697044 Review. - Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications.
Cardinali DP, Cano P, Jiménez-Ortega V, Esquifino AI. Cardinali DP, et al. Neuroendocrinology. 2011;93(3):133-42. doi: 10.1159/000324699. Epub 2011 Feb 25. Neuroendocrinology. 2011. PMID: 21358175 Review. - Metabolic syndrome, its pathophysiology and the role of melatonin.
Srinivasan V, Ohta Y, Espino J, Pariente JA, Rodriguez AB, Mohamed M, Zakaria R. Srinivasan V, et al. Recent Pat Endocr Metab Immune Drug Discov. 2013 Jan;7(1):11-25. Recent Pat Endocr Metab Immune Drug Discov. 2013. PMID: 22946959 Review. - [Metabolic syndrome and melatonin].
Rapoport SI, Molchanov AIu, Golichenkov VA, Burlakova OV, Suprunenko ES, Savchenko ES. Rapoport SI, et al. Klin Med (Mosk). 2013;91(11):8-14. Klin Med (Mosk). 2013. PMID: 25696959 Review. Russian.
Cited by
- Is Melatonin the "Next Vitamin D"?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements.
Minich DM, Henning M, Darley C, Fahoum M, Schuler CB, Frame J. Minich DM, et al. Nutrients. 2022 Sep 22;14(19):3934. doi: 10.3390/nu14193934. Nutrients. 2022. PMID: 36235587 Free PMC article. Review. - Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort.
Foiselle M, Barbosa S, Godin O, Wu CL, Boukouaci W, Andre M, Aouizerate B, Berna F, Barau C, Capdevielle D, Vidailhet P, Chereau I, Davidovic L, Dorey JM, Dubertret C, Dubreucq J, Faget C, Fond G, Leigner S, Llorca PM, Mallet J, Misdrahi D, Martinuzzi E, Passerieux C, Rey R, Pignon B, Urbach M, Schürhoff F, Glaichenhaus N, Leboyer M, Tamouza R; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Groups. Foiselle M, et al. Brain Behav Immun Health. 2022 Mar 29;22:100436. doi: 10.1016/j.bbih.2022.100436. eCollection 2022 Jul. Brain Behav Immun Health. 2022. PMID: 35469211 Free PMC article. - Circadian Rhythms, Chrononutrition, Physical Training, and Redox Homeostasis-Molecular Mechanisms in Human Health.
Drăgoi CM, Nicolae AC, Ungurianu A, Margină DM, Grădinaru D, Dumitrescu IB. Drăgoi CM, et al. Cells. 2024 Jan 11;13(2):138. doi: 10.3390/cells13020138. Cells. 2024. PMID: 38247830 Free PMC article. Review. - Obesity in people with diabetes in COVID-19 times: Important considerations and precautions to be taken.
Alberti A, Schuelter-Trevisol F, Iser BPM, Traebert E, Freiberger V, Ventura L, Rezin GT, da Silva BB, Meneghetti Dallacosta F, Grigollo L, Dias P, Fin G, De Jesus JA, Pertille F, Rossoni C, Hur Soares B, Nodari Júnior RJ, Comim CM. Alberti A, et al. World J Clin Cases. 2021 Jul 16;9(20):5358-5371. doi: 10.12998/wjcc.v9.i20.5358. World J Clin Cases. 2021. PMID: 34307590 Free PMC article. Review. - The Melatonin-Mitochondrial Axis: Engaging the Repercussions of Ultraviolet Radiation Photoaging on the Skin's Circadian Rhythm.
Gao T, Li Y, Wang X, Ren F. Gao T, et al. Antioxidants (Basel). 2023 Apr 26;12(5):1000. doi: 10.3390/antiox12051000. Antioxidants (Basel). 2023. PMID: 37237866 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous